These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 30991411)

  • 1. Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease.
    Sakashita M; Tanaka T; Nangaku M
    Contrib Nephrol; 2019; 198():112-123. PubMed ID: 30991411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
    Kurata Y; Tanaka T; Nangaku M
    Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):414-422. PubMed ID: 32452915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease.
    Hasegawa S; Tanaka T; Nangaku M
    Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):331-338. PubMed ID: 30067604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.
    Kular D; Macdougall IC
    Pediatr Nephrol; 2019 Mar; 34(3):365-378. PubMed ID: 29569190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond.
    Maxwell PH; Eckardt KU
    Nat Rev Nephrol; 2016 Mar; 12(3):157-68. PubMed ID: 26656456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
    Mima A
    Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Characterization of Vadadustat (AKB-6548), an Oral Small Molecule Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, for the Potential Treatment of Renal Anemia.
    Zuk A; Si Z; Loi S; Bommegowda S; Hoivik D; Danthi S; Molnar G; Csizmadia V; Rabinowitz M
    J Pharmacol Exp Ther; 2022 Oct; 383(1):11-24. PubMed ID: 35926869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
    Maruno S; Tanaka T; Nangaku M
    Rinsho Ketsueki; 2021; 62(5):371-377. PubMed ID: 34108317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
    Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
    Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients with Chronic Kidney Disease and Renal Anemia.
    Packer M
    Am J Nephrol; 2024; 55(2):255-259. PubMed ID: 37231827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
    Chen H; Cheng Q; Wang J; Zhao X; Zhu S
    J Clin Pharm Ther; 2021 Aug; 46(4):999-1009. PubMed ID: 33615523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.
    Sugahara M; Tanaka T; Nangaku M
    Pharmacol Ther; 2022 Nov; 239():108272. PubMed ID: 36031160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
    Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
    J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience.
    Sanghani NS; Haase VH
    Adv Chronic Kidney Dis; 2019 Jul; 26(4):253-266. PubMed ID: 31477256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors
    Yang J; Xing J; Zhu X; Xie X; Wang L; Zhang X
    Front Endocrinol (Lausanne); 2023; 14():1131516. PubMed ID: 37008953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease.
    Kaplan JM; Sharma N; Dikdan S
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis.
    Li J; Xie QH; You L; Xu NX; Hao CM
    Pharmacol Res; 2021 Jan; 163():105256. PubMed ID: 33086081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects.
    Akizawa T; Tsubakihara Y; Nangaku M; Endo Y; Nakajima H; Kohno T; Imai Y; Kawase N; Hara K; Lepore J; Cobitz A
    Am J Nephrol; 2017; 45(2):127-135. PubMed ID: 27978511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.